Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) Bundle
Investors watching Shanghai Tongji Science & Technology Industrial Co., Ltd. will find a mixed financial portrait: Q1 2025 revenue fell to 903 million yuan (down 9.39% YoY) while TTM revenue as of Nov 3, 2025 stood at 3.58 billion yuan (down 12.02%), and 2024 annual revenue registered 4.17 billion yuan (down 26.44% vs. 2023); yet profitability shows resilience with Q1 2025 net income attributable to shareholders of 87.52 million yuan (up 16.97% YoY), a TTM net profit margin near 7.4% and EPS of 0.43 yuan, even as valuation metrics signal premium expectations - P/E at 37.10 and P/S at 2.58 against a market cap of 9.22 billion yuan; the balance sheet reveals conservative posture with cash and equivalents of 2.47 billion yuan versus total debt of 2.34 billion yuan (total debt-to-equity 36.13%) but liquidity pressures persist (current ratio 1.371, quick ratio 0.73) alongside modest operating cash flow (TTM 153.18 million yuan) and strategic growth levers such as a planned 55% acquisition of Tongji Testing, potential EPS expansion to 0.70 by 2025 per analyst expectations, and a 0.20 yuan dividend (≈31% payout ratio)-read on for a line-by-line breakdown of revenue drivers, margins, leverage, valuation and risks that investors need to weigh.
Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) - Revenue Analysis
Recent topline trends show sustained pressure on Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) revenue across multiple horizons: quarterly, annual, and TTM figures indicate declines that are material for investors assessing growth durability and valuation.
| Period | Revenue (CNY) | Change vs. Prior Period | Notes |
|---|---|---|---|
| Q1 2025 | 903,000,000 | -9.39% YoY | Quarterly weakness |
| TTM as of 2025-11-03 | 3,580,000,000 | -12.02% YoY | Trailing twelve months |
| FY 2024 | 4,170,000,000 | -26.44% vs. 2023 | Significant annual contraction |
| Revenue per employee (2024) | 1,070,000 | - | Based on 3,334 employees |
| Market capitalization (2025-11-03) | 9,220,000,000 | - | Market valuation snapshot |
| Price-to-Sales (P/S) | 2.58 | - | Market valuation relative to revenue |
- Topline compression: FY2024 revenue down 26.44% vs. 2023, with TTM (-12.02%) and Q1 2025 (-9.39% YoY) confirming persisting decline.
- Operational efficiency: revenue per employee ~1.07 million CNY suggests headcount scale (3,334 employees) relative to revenue generation.
- Valuation context: market cap 9.22 billion CNY and P/S 2.58 imply the market prices continued revenue recovery potential rather than current growth momentum.
Key implications for investors include monitoring quarterly revenue trajectory for signs of stabilization or further deterioration, evaluating margins and cash flow to see if the company can sustain operations at lower revenue levels, and comparing P/S to peers for relative valuation. For broader investor context and shareholder composition, see: Exploring Shanghai Tongji Science&Technology Industrial Co.,Ltd Investor Profile: Who's Buying and Why?
Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) - Profitability Metrics
Key profitability indicators for Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) reveal a company with modest margins, improving short-term earnings and steady capital efficiency. Below are the principal metrics investors should note for recent performance and trailing twelve-month (TTM) measures.
- Net income attributable to shareholders (Q1 2025): 87.52 million yuan, up 16.97% year-on-year.
- Net profit margin (TTM): ~7.4%.
- Earnings per share (EPS, TTM): 0.43 yuan.
- Return on equity (ROE): 6.3%.
- Operating margin (TTM): 6.16%.
- Gross margin: 14.03%.
| Metric | Value | Period | Interpretation |
|---|---|---|---|
| Net income attributable to shareholders | 87.52 million CNY | Q1 2025 | Double-digit YoY growth (16.97%) indicating improved quarterly profitability |
| Net profit margin | 7.4% | TTM | Moderate conversion of revenue to net earnings |
| EPS | 0.43 CNY | TTM | Per-share earnings supporting valuation models |
| ROE | 6.3% | Latest reported | Modest shareholder return; room for improvement in capital efficiency |
| Operating margin | 6.16% | TTM | Operational profitability after operating expenses |
| Gross margin | 14.03% | Latest reported | Indicates the percentage of revenue remaining after COGS |
For context on strategic direction and how these profitability metrics tie into long-term plans, see: Mission Statement, Vision, & Core Values (2026) of Shanghai Tongji Science&Technology Industrial Co.,Ltd.
Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) - Debt vs. Equity Structure
Key balance-sheet metrics as of the latest reported dates show a conservative capital structure with substantial liquidity relative to liabilities.
| Metric | Value | Unit / Note |
|---|---|---|
| Total debt (as of 2025-03-31) | 1.33 billion | yuan |
| Total debt (aggregate referenced) | 2.34 billion | yuan |
| Debt-to-equity ratio | 36.13% | total debt / shareholders' equity |
| Current ratio | 1.371 | current assets / current liabilities |
| Cash and cash equivalents | 2.47 billion | yuan |
| Book value per share | 5.819 | yuan per share |
- Liquidity buffer: cash and equivalents (2.47 billion yuan) roughly match or exceed the referenced total debt figure (2.34 billion yuan), reducing refinancing risk.
- Moderate leverage: a 36.13% debt-to-equity ratio signals balanced use of debt without aggressive gearing.
- Short-term coverage: current ratio of 1.371 indicates short-term assets sufficiently cover current liabilities, though not excessively high.
- Per-share backing: book value per share of 5.819 yuan provides an equity floor for shareholders.
Implications for capital allocation and investor risk:
- Financial flexibility - near-parity of cash to debt allows the company to service obligations while retaining capacity for opportunistic investment or acquisitions.
- Resilience to shocks - moderate leverage combined with positive current ratio reduces operational and solvency risk in downturns.
- Return vs. safety trade-off - conservative balance sheet supports stability but may constrain return-enhancing leverage strategies.
For broader context on corporate direction and values that may affect capital decisions, see: Mission Statement, Vision, & Core Values (2026) of Shanghai Tongji Science&Technology Industrial Co.,Ltd.
Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) - Liquidity and Solvency
Key liquidity and solvency metrics for Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) show a generally conservative balance-sheet posture with specific short-term liquidity constraints if inventory cannot be converted quickly.
- Current ratio: 1.371 - sufficient to cover short-term liabilities with short-term assets, but not overly liquid.
- Quick ratio: 0.73 - below 1.0, indicating reliance on inventory to meet near-term obligations.
- Operating cash flow (TTM): ¥153.18 million - positive cash from core operations.
- Half-year net income (6/30/2025): ¥146.34 million vs. ¥233.24 million (6/30/2024) - notable year-over-year decline.
- Cash & cash equivalents: ¥2.47 billion vs. Total debt: ¥2.34 billion - cash roughly covers gross debt.
- Total debt-to-equity ratio: 36.13% - moderate leverage.
| Metric | Value | Context/Implication |
|---|---|---|
| Current Ratio | 1.371 | Meets short-term obligations but limited buffer |
| Quick Ratio | 0.73 | Potential difficulty covering liabilities without selling inventory |
| Operating Cash Flow (TTM) | ¥153.18 million | Positive operational cash generation |
| Net Income (H1 2025) | ¥146.34 million | Down from ¥233.24 million in H1 2024 |
| Cash & Cash Equivalents | ¥2.47 billion | Significant liquidity reserve |
| Total Debt | ¥2.34 billion | Comparable to cash holdings |
| Debt-to-Equity Ratio | 36.13% | Moderate leverage; conservative capital structure |
Practical takeaways:
- Liquidity profile is stabilized by large cash balances, but the quick ratio below 1 signals potential short-term pressure if inventory turnover slows.
- Operating cash flow is positive but modest relative to cash holdings, and the H1 2025 net income decline warrants monitoring of profitability trends and drivers.
- Debt levels are moderate; with ¥2.47 billion cash against ¥2.34 billion debt the company holds a net cash-like position on a gross basis, supporting solvency metrics and financial flexibility.
For broader strategic context and corporate priorities, see: Mission Statement, Vision, & Core Values (2026) of Shanghai Tongji Science&Technology Industrial Co.,Ltd.
Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) Valuation Analysis
This section breaks down market valuation and balance-sheet context for Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) using the latest available figures (as of November 3, 2025) to help investors gauge relative price levels, profitability per share, revenue valuation and leverage posture.
- Price-to-Earnings (P/E): 37.10 - the market is pricing the stock at 37.10 times trailing earnings, implying relatively high expectations for future growth or momentum in earnings quality.
- Price-to-Sales (P/S): 2.58 - investors pay 2.58 yuan per yuan of revenue, a moderate revenue multiple versus peers in industrial/technology segments.
- Earnings Per Share (TTM EPS): 0.43 yuan - the base earnings used in the P/E calculation.
- Market Capitalization: 9.22 billion yuan (as of 2025-11-03) - the company's total listed equity value.
- Liquidity vs. Debt: Cash and cash equivalents 2.47 billion yuan; Total debt 2.34 billion yuan - a net cash/low-net-debt position supporting financial flexibility.
- Total Debt-to-Equity: 36.13% - moderate leverage, indicating conservative capital structure relative to equity base.
| Metric | Value | Notes |
|---|---|---|
| Price-to-Earnings (P/E) | 37.10 | Trailing twelve months basis |
| Price-to-Sales (P/S) | 2.58 | Market cap / Revenue |
| Earnings Per Share (EPS, TTM) | 0.43 yuan | Used for P/E calculation |
| Market Capitalization | 9.22 billion yuan | As of 2025-11-03 |
| Cash & Cash Equivalents | 2.47 billion yuan | Highly liquid buffer |
| Total Debt | 2.34 billion yuan | Includes short- and long-term borrowings |
| Total Debt-to-Equity | 36.13% | Moderate leverage level |
For context on the company's broader background, ownership and business model, see: Shanghai Tongji Science&Technology Industrial Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money
Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) - Risk Factors
Key financial metrics and trends that investors should weigh when assessing risk exposure for Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS):
- Profitability pressure: reported net profit margin of 7.4%, signaling limited operating leverage and thinner buffers against cost shocks or revenue declines.
- Liquidity constraint: quick ratio of 0.73, indicating potential difficulty meeting short-term liabilities without relying on inventory conversion or external financing.
- Leverage profile: total debt-to-equity ratio of 36.13%, a moderate leverage level that increases fixed-charge and refinancing risk in tougher markets.
- Cash vs. debt: cash and cash equivalents of ¥2.47 billion versus total debt of ¥2.34 billion - a conservative liquidity cushion but one that must be managed carefully if earnings weaken.
- Declining earnings: net income fell to ¥146.34 million for the half-year ended June 30, 2025, from ¥233.24 million in the same period a year earlier, highlighting earnings volatility and potential margin compression.
- Recurring margin concern: the 7.4% net profit margin repeats as a persistent constraint on capital accumulation and reinvestment capacity.
| Metric | Value | Period / Note |
|---|---|---|
| Net Profit Margin | 7.4% | Reported (persistent) |
| Quick Ratio | 0.73 | Short-term liquidity |
| Cash & Cash Equivalents | ¥2.47 billion | On balance sheet |
| Total Debt | ¥2.34 billion | On balance sheet |
| Total Debt-to-Equity Ratio | 36.13% | Capital structure |
| Net Income - H1 2025 | ¥146.34 million | Half-year ended 30 Jun 2025 |
| Net Income - H1 2024 | ¥233.24 million | Half-year ended 30 Jun 2024 |
Risk implications for investors:
- With a 7.4% net margin, adverse revenue or cost shifts could quickly erode profits and cash flow available for dividends, capex, or debt service.
- A quick ratio below 1.0 means working capital management and AR/receivable conversion are critical; unexpected draws on liquidity could force asset sales or short-term borrowings.
- Although cash slightly exceeds total debt (¥2.47bn vs ¥2.34bn), a declining net income trend (¥146.34m vs ¥233.24m y/y) reduces internal funding capacity and increases sensitivity to interest rate or refinancing cycles.
- Moderate debt-to-equity (36.13%) provides some financial flexibility, but capital-intensive investments or M&A could raise leverage quickly if not funded by improved operating cash flow.
- Repeated emphasis on the 7.4% margin underscores limited margin of safety; operational or market disruptions may have outsized effects on valuation and credit metrics.
For broader context on corporate background, governance and business model: Shanghai Tongji Science&Technology Industrial Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money
Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) - Growth Opportunities
- Planned acquisition: proposed purchase of a 55% stake in Tongji Testing to extend the engineering consulting industry chain and capture testing/validation margins.
- EPS trajectory: analysts project EPS rising from $0.50 in 2023 to $0.70 by 2025, implying ~40% cumulative EPS growth over two years.
- International partnerships: strategic alliances with overseas firms to co-develop advanced materials and technologies, aiming to upgrade product mix and expand addressable markets.
- Shareholder returns: dividend per share of 0.20 yuan, representing a payout ratio of approximately 31% on current EPS.
- Conservative balance sheet: cash and cash equivalents of 2.47 billion yuan against total debt of 2.34 billion yuan, supporting acquisitions and R&D spending.
- Leverage profile: total debt-to-equity ratio of 36.13%, indicating a moderate debt load that allows room for strategic investment without aggressive refinancing risk.
| Metric | Value / Projection | Notes |
|---|---|---|
| Planned acquisition | 55% stake in Tongji Testing | Strengthens engineering consulting chain |
| EPS (2023) | $0.50 | Reported / consensus base |
| EPS (2025 projected) | $0.70 | Analysts' projection |
| Dividend per share | 0.20 yuan | Payout ratio ≈ 31% |
| Cash & cash equivalents | 2.47 billion yuan | Provides liquidity for M&A / capex |
| Total debt | 2.34 billion yuan | Manageable given cash position |
| Total debt-to-equity | 36.13% | Moderate leverage |
- Revenue growth drivers: expanding consulting/testing services via Tongji Testing acquisition, higher-margin materials/tech from international collaborations, and cross-selling within existing industrial customer base.
- Capital allocation priorities: targeted M&A (55% Tongji Testing), continued R&D partnerships, and maintaining shareholder distributions (0.20 yuan DPS).
- Risk considerations: integration risk from the Tongji Testing acquisition, execution risk on international tech partnerships, and currency/market exposure tied to overseas collaborations.

Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.